Committed to improving the lives of patients

We work to transform the lives of the patients we serve. Meeting their individual needs is what drives our science and provides our focus.

Ryan
High school principal, outdoorsman, husband and father

news
Diagnosed with MS as a teen, Ryan has gone on to lead a highly active lifestyle. Learn more about his incredible journey.

The stories that inspire our science

Meet some of our patients and hear their stories in their own words. 

Extending our support in meaningful ways

We believe our therapies can be even more effective when backed by services that support patients emotionally, financially and medically.

Multiple sclerosis (MS) support

  • Multiple sclerosis (MS) support
  • Hemophilia support
  • Partnered therapy support
Multiple sclerosis (MS) support | 1-800-456-2255 MSActiveSource.com

Multiple sclerosis (MS) support

As part of our ongoing commitment to patients, Biogen provides a variety of support services for patients and care partners through Biogen MS Support. These world-class services are thoughtfully crafted around the informational, emotional, financial and logistical needs that come with living with the diseases our products treat.

For current patients, we offer:

  • Financial access: Benefit investigation to help you understand your coverage options, and a $0 copay program from Biogen. Call 1-800-456-2255 to see if you’re eligible.
  • Nurse hotline: Access to 24/7 trained nurse educational support, as well as home visits for one-on-one injection training (if needed).
  • Ongoing support: Unlimited one-on-one telephone support, including scheduled follow-up calls to help with treatment and wellness support.
  • Peer mentorship: Mentoring program that connects you with a community of peers who can help by sharing their experiences with relapsing MS.

To access these and other services, please contact us:
1-800-456-2255
Monday–Friday, 8:30 a.m.–8 p.m. ET
www.MSActiveSource.com

Hemophilia support | MyELOCTATE | 1-855-MyELOCTATE MyALPROLIX | 1-855-MyALPROLIX

Hemophilia support

At Biogen, we have listened to the people affected by hemophilia and are providing comprehensive access and assistance programs shaped by community input. We are committed to enabling access to therapy; our goal is for no one to forgo treatment based on financial limitations or insurance status. We offer a variety of personalized assistance and resources through MyELOCTATE™ Services and MyALPROLIX™ Services.

Everyone who calls into MyELOCTATE or MyALPROLIX will talk to a coordinator who will provide dedicated, one-on-one assistance: someone who will work with the individual and tailor resources to help meet their needs. To support access to therapy, these highly trained coordinators will work directly with people with hemophilia, their loved ones, healthcare providers, pharmacies and home healthcare teams. For clinicians, the programs provide a range of professional support materials to facilitate the use of Biogen therapies for appropriate individuals.

Coordinators provide people with hemophilia and their families with:

  • Assistance on how to receive therapy or with monthly out-of-pocket costs
  • Support for continued access to treatment, including if they have a lapse in insurance coverage or have reached their cap
  • A better understanding of their insurance coverage options.

To learn more about these services, please call or visit:

MyELOCTATE – hemophilia A resources
1-855-MyELOCTATE (1-855-693-5628)
Monday–Friday, 8 a.m.–10 p.m. ET
www.ELOCTATE.com

MyALPROLIX - hemophilia B resources
1-855-MyALPROLIX (1-855-692-5776)
Monday–Friday, 8 a.m.–10 p.m. ET
www.ALPROLIX.com

Partnered therapy support | RITUXAN support service | 1-877-474-8892 GAZYVA support service | 1-877-218-3996

Partnered therapy support

RITUXAN® (rituximab) and GAZYVA® (obinutuzumab) patient support is managed by Genentech, a member of Roche Group.

RITUXAN support service

1-877-474-8892
Monday–Friday, 8 a.m.–11 p.m. ET; Saturday, 9 a.m.–1 p.m. ET

GAZYVA support service

1-877-218-3996
24 hours a day, 7 days a week

Multiple sclerosis (MS) support | 1-800-456-2255 MSActiveSource.com
Hemophilia support | MyELOCTATE | 1-855-MyELOCTATE MyALPROLIX | 1-855-MyALPROLIX
Partnered therapy support | RITUXAN support service | 1-877-474-8892 GAZYVA support service | 1-877-218-3996

Dedicated to new discoveries

Our pipeline is more than a list of medicines in development. It reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients.

Filter By:
All Therapeutic Areas"
  • All Therapeutic Areas"
  • Neurology
  • Hematology
  • Immunology
All phases
  • All phases
  • Filed
  • Phase 3
  • Phase 2
  • Phase 1
Phase
  • 01Phase 1
  • 02 Phase 2
  • 03Phase 3
  • Filed
  • Daclizumab High-Yield Process (DAC HYP)

    Relapsing-remitting multiple sclerosis (MS)

    Developed in collaboration with AbbVie Biotherapeutics.

    This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to the myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking.

    How this therapy could help:

    Patients who have relapsing-remitting MS experience attacks, or relapses, of neurologic impairment, followed by periods of partial or complete recovery. DAC HYP is an antibody that binds to CD25, a receptor highly expressed in immune cells abnormally activated in MS. Binding DAC HYP and CD25 may normalize immune cell activity, possibly preventing relapses and slowing the progress of the disease.

  • ISIS-SMNrx

    Spinal muscular atrophy (SMA)

    Developed in collaboration with Isis Pharmaceuticals.

    People with this rare, inherited genetic disease lack a protein called SMN that helps with muscle control. Children born with SMA have difficulty eating, often miss developmental milestones and experience muscle weakness and wasting in the legs, arms and torso. SMA can lead to death by respiratory failure at a young age.

    How this therapy could help:

    ISIS-SMNrx is thought to promote the production of functional SMN protein, potentially improving the motor function and life span of patients with SMA. 

  • Natalizumab

    Secondary progressive multiple sclerosis (SPMS)

    Currently approved as TYSABRI® for relapsing-remitting multiple sclerosis and Crohn’s disease. Please visit TYSABRI.com for prescribing and safety information.

    MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to the myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking.

    How this therapy could help:

    After a period of experiencing relapses (increased impairment) and remission (improved ability), many MS patients will eventually enter secondary-progressive MS (SPMS): steady progression of neurological damage. Natalizumab may help by potentially reducing the disability progression.

  • Obinutuzumab (GA101)

    Diffuse large B-cell lymphoma (DLBCL)

    Currently approved as GAZYVA® for chronic lymphocytic leukemia (CLL). Please visit GAZVYA.com for prescribing and safety information.

    DLBCL is a type of non-Hodgkin’s lymphoma (NHL), a cancer of the immune system. NHL involves white blood cells (known as lymphocytes). Under normal conditions, these cells help defend the body from disease. In people with NHL, too many abnormal white blood cells build up in the blood, bone marrow, spleen and/or lymph nodes. Most NHL occurs in white blood cells called B cells. Intermediate and high-grade, or fast-growing, tumors are called aggressive NHL. DLBCL is the most common type of aggressive NHL.

     

    How this therapy could help: 

    Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 protein found on the surface of NHL cells. Once attached to the CD20 protein, Obinutuzumab works in two different ways:

    • By helping the immune system destroy cancer cells
    • By destroying cancer cells on its own

     

    We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

  • Obinutuzumab (GA101)

    Indolent non-Hodgkin’s lymphoma, front-line and refractory

    Currently approved as GAZYVA® for chronic lymphocytic leukemia (CLL). Please visit GAZVYA.com for prescribing and safety information.

    Non-Hodgkin’s lymphoma, or NHL, is a type of cancer of the immune system. NHL involves white blood cells (known as lymphocytes). Under normal conditions, these cells help defend the body from disease. In people with NHL, too many abnormal white blood cells build up in the blood, bone marrow, spleen and/or lymph nodes. Most NHL occurs in white blood cells called B cells. Low-grade, or slow-growing, tumors are called indolent NHL. Many patients live with indolent NHL for many years.

    How this therapy could help:
    Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 protein found on the surface of NHL cells. Once attached to the CD20 protein, Obinutuzumab works in two different ways:

    • By helping the immune system destroy cancer cells;
    • By destroying cancer cells on its own.

     

    We collaborate on obinutuzumab in the U.S. with Genentech, Inc., a wholly-owned member of the Roche Group. The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacturing and commercialization of obinutuzumab.

  • Anti-LINGO-1 (BIIB033)

    Multiple sclerosis (MS)

    This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    How this therapy could help:

    LINGO is a neurologic protein that is involved in the development of myelin. In patients with MS, LINGO may inhibit myelin growth when it binds with its normal receptor. Data suggest that the antibody Anti-LINGO-1 could block this process, potentially allowing for the re-myelination and restoration of nerve communication in MS patients

  • Anti-TWEAK

    Lupus nephritis

    This kidney disorder is caused by systemic lupus erythematosus (SLE or lupus). SLE is a chronic inflammatory disease. It occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

    How this therapy could help:

    Scientists have linked TWEAK, an immune cell protein, to increased disease activity in lupus nephritis. When TWEAK binds to its normal receptor, inflammation can be the result. TWEAK binding to the anti-TWEAK antibody could block this process and potentially diminish inflammation.

  • BAN2401 (Humanized anti-amyloid beta mab)

    Alzheimer’s disease

    Developed in collaboration with Eisai Co., Ltd.

    The most common cause of dementia, Alzheimer’s disease is a brain disorder that leads to impairment of intellectual functions and social skills, resulting ultimately in significant disturbance of daily living activities. Dementia is caused by the destruction of cells in certain parts of the brain primarily involved in memory and mental function.

    How this therapy could help:

    The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. BAN2401 is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.

  • CNV1014802

    Trigeminal Neuralgia (TGN)

    Acquired in acquisition of Convergence Pharmaceuticals

    TGN is a very severe form of facial pain that is experienced in short bursts or attacks. TGN is characterized by sudden, severe, brief, stabbing, recurrent episodes of pain usually on one side of the face and that can be provoked by light touch. The pain follows one or more branches of the trigeminal nerve, which provides nerve sensation from the mouth, face and the front of the scalp. The severity of the pain and its unpredictability results in profound effects on the quality of life of patients and often significant depression. The condition is commonly misdiagnosed and, to date, there is no cure for the condition.

    How this therapy could help:

    CNV1014802 is a novel state dependent small molecule sodium channel blocker that preferentially inhibits the Nav 1.7 ion channel, a therapeutic target implicated by genetics in human pain conditions. CNV1014802 is thought to penetrate the central nervous system (CNS) and block Nav channels in a novel manner, resulting in an improved therapeutic profile over currently available agents. 

  • E2609 (BACE1 Inhibitor)

    Alzheimer's disease

    Developed in collaboration with Eisai Co., Ltd.

    The most common cause of dementia, Alzheimer’s disease is a brain disorder that leads to impairment of intellectual functions and social skills, resulting ultimately in significant disturbance of daily living activities. Dementia is caused by the destruction of cells in certain parts of the brain primarily involved in memory and mental function.

    How this therapy could help:

    The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. E2609 is a small-molecule inhibitor of beta-secretase, a protein that cleaves enzyme 1 (BACE1). By inhibiting BACE1, E2609 blocks amyloid production, potentially slowing the progress of the disease.

  • Natalizumab

    Acute Ischemic Stroke

     

    Currently approved as TYSABRI® for relapsing-remitting multiple sclerosis and Crohn’s disease. Please visit TYSABRI.com for prescribing and safety information.

    It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke. 


    How this therapy could help: 

    Natalizumab is thought to reduce the inflammatory cells in the brain by blocking the lymphocytic infiltration, known to occur in the brain following stroke, which may reduce the extent of injury.

     

  • Neublastin (BG00010)

    Neuropathic pain

    People with this condition experience chronic pain. The source of the injury is outwardly invisible since it stems from a problem within the body’s intricate network of nerve fibers. The brain communicates with the rest of the body through this network. When nerve fibers are damaged, malfunctioning or injured, the signals misfire and pain is the result.

    How this therapy could help:

    Standard pain treatments do not work well with this complex condition. Neublastin interacts with receptors on pain-sensing nerves and may promote nerve regeneration. If so, treatment with Neublastin could result in rapid relief for patients with neuropathic pain.

  • STX-100

    Idiopathic pulmonary fibrosis (IPF)

    Pulmonary fibrosis is a disease in which lung tissue becomes thickened and stiff due to scarring. The formation of scar tissue is called fibrosis. As the disease progresses, it becomes harder for the lungs to work properly and the body cannot get the oxygen it needs. This debilitating disease is almost always fatal.

    How this therapy could help:

    The TGF-beta brain cell pathway is involved in several fibrotic diseases. The STX-100 antibody may selectively block the TGF-beta pathway, and may slow the development of fibrosis in IPF patients.

  • Aducanumab (BIIB037)

    Alzheimer’s disease

    The most common cause of dementia, Alzheimer’s disease is a brain disorder that leads to impairment of intellectual functions and social skills, resulting ultimately in significant disturbance of daily living activities. Dementia is caused by the destruction of cells in certain parts of the brain primarily involved in memory and mental function.

    How this therapy could help:

    The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in  the brain. BIIB037 is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.

  • Anti-BDCA2

    Systemic lupus erythematosus (SLE)

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

    How this therapy could help:

    BDCA2 is a protein present in specific cells within the immune system. An antibody against BDCA2 can potentially interrupt production of interferons, inflammatory molecules that are increased in patients with SLE and contribute to disease activity. 

  • Anti-CD40 Ligand

    Systemic lupus erythematosus (SLE)

    Developed in collaboration with UCB, Inc.

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

    How this therapy could help:

    CD40L is a protein in B and T cells, which helps regulate the immune system. Anti-CD40L is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients.

  • BIIB061 (Oral re-myelination)

    Multiple sclerosis (MS)

    This disease causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    How this therapy could help:

    Data suggest that BIIB061 treatment may lead to re-myelination, or the replacement of myelin on damaged nerve fibers.

  • ISIS-DMPKRX

    Myotonic dystrophy, type 1

    Developed in collaboration with Isis Pharmaceuticals

    People with this rare inherited genetic disease have a mutation in the DMPK gene. The mutation can affect multiple organ systems. People with the disease can suffer from weakness and slowed relaxation of contracted muscles (myotonia), as well as heart or breathing problems.

    How this therapy could help:

    ISIS-DMPKRX is anticipated to dampen the expression of the DMPK gene, slowing the disease progression and improving quality of life for patients with myotonic dystrophy, type 1.

Currently no results for this search

Gaining insight through clinical trials

Biogen conducts clinical trials to assess new treatments and to investigate potential new uses and benefits for existing therapies.

Read more about clinical trials 

Clinical trials by Biogen

View clinical trials being conducted by Biogen

Investigators interested in research opportunities

Learn about available research programs for investigators

Learn more about clinical trials

Find out more about our approach to clinical trials

Welcome to the new Biogen

March 23, 2015

Biogen, Once Again

See all perspectives

Biogen Idec is Biogen, Once Again. #Biogen #Innovation #Trust #Commitment www.biogen.com